Background: Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVGs) has historically been associated with a high risk of adverse ischemic events, but there is a paucity of contemporary data on the second-generation drug-eluting stent use within SVG, and the relative importance of high platelet reactivity (HPR) in SVG PCI versus native lesion PCI is unknown. We studied ischemic and bleeding events after SVG PCI and their association with HPR.
Methods And Results: Subjects in the prospective, multicenter ADAPT-DES study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) were stratified according to whether they had PCI of an SVG or a non-SVG lesion. Two-year outcomes were compared between groups using univariate and multivariable Cox proportional hazards models. HPR was defined as on-clopidogrel P2Y12 platelet reaction units >208 as measured by the VerifyNow assay; major adverse cardiac events were defined as the composite of cardiac death, myocardial infarction, or stent thrombosis. Among 8582 subjects in ADAPT-DES, 405 (4.7%) had SVG PCI. SVG PCI was independently associated with a higher 2-year risk of major adverse cardiac events (adjusted hazard ratio, 2.34; 95% confidence interval, 1.69-3.23; <0.0001), ischemia-driven target vessel revascularization (adjusted hazard ratio, 1.82; 95% confidence interval, 1.37-2.42; <0.0001), and stent thrombosis (adjusted hazard ratio, 2.26; 95% confidence interval, 1.42-3.59; =0.0006), but not of bleeding (adjusted hazard ratio, 0.99; 95% confidence interval, 0.68-1.46; =0.97). There was no statistical interaction between HPR and SVG PCI in regard to major adverse cardiac events (adjusted =0.99).
Conclusions: SVG PCI is associated with a considerably higher risk of 2-year adverse ischemic events, with HPR conferring similar risk in SVG and non-SVG PCI. More potent and longer antiplatelet therapy may be beneficial for patients undergoing SVG PCI.
Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00638794.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/CIRCINTERVENTIONS.117.004953 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictive value of the Naples prognostic score for no-reflow phenomenon after saphenous vein graft stenting.
Biomark Med
January 2025
Department of Cardiology, Kartal Kosuyolu Research and Education Hospital, Kartal, Istanbul, Turkey.
Background: No-reflow is a critical adverse event associated with percutaneous coronary intervention (PCI), particularly during saphenous vein graft (SVG) procedures. The Naples Prognostic Score (NPS) reflects inflammatory status, but its relationship with no-reflow remains unclear. Therefore, we aimed to evaluate the relationship between NPS and no-reflow occurrence following SVG PCI.
View Article and Find Full Text PDFModest dilation using rotational atherectomy and drug-coated balloon for native coronary proximal lesion with patent internal thoracic artery graft.
J Cardiol Cases
December 2024
Department of Cardiology, Kyoto Saiseikai Hospital, Nagaokakyo, Japan.
Unlabelled: Intervention to proximal lesions should be avoided in graft-protected native coronary arteries in general, because there might be a risk for bypass-graft failure. An 81-year-old man with coronary artery bypass grafting surgery due to 3-vessel disease 17 years previously complained of worsening angina. Coronary angiography (CAG) revealed a diseased saphenous vein graft (SVG) and a probable functional occlusion in the mid left anterior descending coronary artery (LAD) concomitant with calcified severe stenosis in the left main (LM)-proximal LAD, and patent right internal thoracic artery (RITA)-LAD graft.
View Article and Find Full Text PDFGender-Related Outcomes in Saphenous Vein Graft Interventions.
Catheter Cardiovasc Interv
December 2024
Department of Cardiology, Rabin Medical Center, Petach Tikva, Israel.
Background: Saphenous vein graft percutaneous coronary intervention (SVG-PCI) is a relatively common procedure in patients after coronary artery bypass grafting (CABG). Although internal mammary artery is considered optimal, SVG is still used in the majority of patients.
Aims: Investigating the potential role of gender differences in the incidence and outcomes of SVG-PCI.
Gender differences in the incidence of saphenous vein graft intervention.
J Cardiothorac Surg
December 2024
Department of Cardiology, Barzilai Medical Center, The Ben-Gurion University of the Negev, Hahistadrout 2, 7830604, Ashkelon, Israel.
Article Synopsis
- The study investigated gender differences in outcomes of saphenous vein graft percutaneous coronary intervention (SVG PCI) after coronary artery bypass grafting (CABG) among patients treated for acute coronary syndrome (ACS).
- Researchers analyzed data from 72 patients at Barzilai Medical Center between 2010 and 2023, finding that men had higher SVG PCI rates, while women experienced earlier graft failures.
- The findings suggest that gender-specific strategies in post-CABG care could enhance patient outcomes and emphasize the importance of tailoring follow-up interventions based on patient gender.
Outcome of Saphenous Vein Graft Percutaneous Coronary Intervention Using Contemporary Drug-Eluting Stents: A SCAAR Report.
J Soc Cardiovasc Angiogr Interv
October 2024
Department of Cardiology, Västerås Hospital, Västerås, Sweden.
Background: Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVG) is associated with poor outcomes and is often regarded as inferior to native vessel PCI. We investigated clinical outcomes of SVG-PCI using contemporary drug-eluting stents (DES), in a complete, nationwide population.
Methods: The complete Swedish Coronary Angiography and Angioplasty Registry (SCAAR) was used to identify all patients in Sweden who underwent SVG-PCI with a contemporary DES between 2013 and 2020.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!